{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:58:30Z","timestamp":1761843510011},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,4,19]],"date-time":"2006-04-19T00:00:00Z","timestamp":1145404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,11,2]]},"DOI":"10.1007\/s00280-006-0242-5","type":"journal-article","created":{"date-parts":[[2006,4,18]],"date-time":"2006-04-18T09:36:04Z","timestamp":1145352964000},"page":"51-59","source":"Crossref","is-referenced-by-count":18,"title":["A phase I\u2013II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane\u00a0+\u00a0platinum-based regimens"],"prefix":"10.1007","volume":"59","author":[{"given":"Christos","family":"Kosmas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Tsavaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelos","family":"Koutras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Tsakonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Makatsoris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Karabelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George P.","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralambos P.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,4,19]]},"reference":[{"key":"242_CR1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O\u2019Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095\u20132103","journal-title":"J Clin Oncol"},{"key":"242_CR2","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354\u20132362","journal-title":"J Clin Oncol"},{"key":"242_CR3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2000.18.1.122","volume":"18","author":"AB Sandler","year":"2000","unstructured":"Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122\u2013130","journal-title":"J Clin Oncol"},{"key":"242_CR4","unstructured":"Garfield DH, Dakhil SR, Whittaker TL, Keller AM (1998) Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:484a (abstract 1863)"},{"key":"242_CR5","unstructured":"Rosvold E, Langer CJ, Scholder R, Millenson M, Reimet E, Kreamer K (1998) Salvage therapy with gemcitabine in advanced non-small cell lung cancer progressing after prior carboplatin-paclitaxel. Proc Am Soc Clin Oncol 17:463a (abstract 1797)"},{"key":"242_CR6","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.1999.17.7.2081","volume":"17","author":"L Crino","year":"1999","unstructured":"Crino L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M (1999) Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 17:2081\u20132085","journal-title":"J Clin Oncol"},{"key":"242_CR7","doi-asserted-by":"crossref","unstructured":"Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T for the CPT-11 Lung Cancer Study Group (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16\u201320","DOI":"10.1200\/JCO.1992.10.1.16"},{"key":"242_CR8","unstructured":"Douillard JY, Ibrahim N, Riviere A, Spaeth D, Chomy P, Soussan K, Mathieu-Boue A (1995) Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:365a (abstract 1118)"},{"key":"242_CR9","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2002.20.5.1182","volume":"20","author":"CM Rocha-Lima","year":"2002","unstructured":"Rocha-Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR (2002) Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182\u20131191","journal-title":"J Clin Oncol"},{"issue":"Suppl. 16","key":"242_CR10","first-page":"43","volume":"26","author":"CM Rocha-Lima","year":"1999","unstructured":"Rocha-Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR (1999) Single-agent gemcitabine and gemcitabine\/irinotecan combination (IrimoGem) in non-small cell lung cancer. Semin Oncol 26(Suppl. 16):43\u201350","journal-title":"Semin Oncol"},{"key":"242_CR11","unstructured":"Bahadori HR, Ogretmen B, Rocha-Lima CM, Green MR, Safa AR (1998) Evaluation of irinotecan (CPT-11) and gemcitabine (G) as single agents and in combination in small-cell lung cancer cells. Proc Am Soc Clin Oncol 17:477a (abstract 1837)"},{"key":"242_CR12","first-page":"58","volume":"2","author":"CMS Rocha-Lima","year":"1999","unstructured":"Rocha-Lima CMS, Leong SS, Sherman CA (1999) Phase I study of CPT-11 and gemcitabine in patients with solid tumors. Cancer Ther 2:58\u201366","journal-title":"Cancer Ther"},{"key":"242_CR13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ijc.10162","volume":"98","author":"C Kosmas","year":"2002","unstructured":"Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP (2002) A phase I\u2013II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. Int J Cancer 98:141\u2013147","journal-title":"Int J Cancer"},{"key":"242_CR14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000089681","volume":"69","author":"C Kosmas","year":"2005","unstructured":"Kosmas C, Tsavaris N, Koutras A, Makatsoris T, Mylonakis N, Tzelepis G, Dimitrakopoulos A, Spyropoulos K, Polyzos A, Karabelis A, Kalofonos HP (2005) A Phase II study of the docetaxel\u2013ifosfamide\u2013carboplatin combination in advanced non-small-cell lung cancer. Oncology 69:333\u2013341","journal-title":"Oncology"},{"key":"242_CR15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/1097-0142(20000815)89:4<774::AID-CNCR9>3.0.CO;2-5","volume":"89","author":"C Kosmas","year":"2000","unstructured":"Kosmas C, Tsavaris N, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ (2000) A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer. Cancer 89:774\u2013782","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"242_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0959-8049(05)80262-X","volume":"29A","author":"PJ Hollen","year":"1993","unstructured":"Hollen PJ, Gralla RJ, Kris MG, Potanovich LM (1993) Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale. Eur J Cancer 29A(Suppl. 1):51\u201358","journal-title":"Eur J Cancer"},{"key":"242_CR17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1959","unstructured":"Kaplan EL, Meier P (1959) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"242_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"242_CR19","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1200\/JCO.1989.7.11.1602","volume":"7","author":"PD Bonomi","year":"1989","unstructured":"Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602\u20131613","journal-title":"J Clin Oncol"},{"key":"242_CR20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589\u20131597","journal-title":"J Clin Oncol"},{"key":"242_CR21","first-page":"2499","volume":"8","author":"P Pourquier","year":"2002","unstructured":"Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, Pommier Y (2002) Gemcitabine (2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 8:2499\u20132504","journal-title":"Clin Cancer Res"},{"key":"242_CR22","unstructured":"O\u2019Reilly E, Ilson D, Schwartz G, Tong W, Fata F, Kemeny N, Sherwin K, Sharma S, Kelsen D (1999) A phase I study of combination gemcitabine (gem) and irinotecan (CPT-11) in patients (pts) with refractory solid Tumors. Proc Am Soc Clin Oncol 18:176a (abstract 674)"},{"key":"242_CR23","first-page":"1891","volume":"22","author":"SS Kakolyris","year":"2002","unstructured":"Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, Georgoulias V (2002) A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 22:1891\u20131896","journal-title":"Anticancer Res"},{"key":"242_CR24","unstructured":"Rocha-Lima CMS, Rizvi NA, Zhang K, Herndon JE, Crawford J, King GW, Green MR (2002) CALGB 39809: randomized phase II trial of gemcitabine\/irinotecan and gemcitabine\/docetaxel in stage IIIB (malignant pleural effusion) or stage IV NSCLC. Proc Am Soc Clin Oncol 21:337a (abstract 1344)"},{"key":"242_CR25","first-page":"237","volume":"30","author":"H Ryo","year":"2003","unstructured":"Ryo H, Toyama K, Isobe K, Sugino K, Sano G, Yamada H, Hiroi M, Hojyo T, Kimura K (2003) A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer. Gan To Kagaku Ryoho 30:237\u2013242","journal-title":"Gan To Kagaku Ryoho"},{"key":"242_CR26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/sj.bjc.6602010","volume":"91","author":"V Georgoulias","year":"2004","unstructured":"Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I, Lung Cancer Committee of the Hellenic Oncology Research Group (2004) Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 91:482\u2013488","journal-title":"Br J Cancer"},{"key":"242_CR27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2004.09.006","volume":"48","author":"M Nishio","year":"2005","unstructured":"Nishio M, Ohyanagi F, Taguch F, Matsuda M, Sato Y, Okumura S, Nakagawa K, Horai T (2005) Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer. Lung Cancer 48:115\u2013119","journal-title":"Lung Cancer"},{"key":"242_CR28","doi-asserted-by":"crossref","unstructured":"Ohyanagi F, Nishio M, Horai T, Kasahara K, Shibata K, Takeda Y (2004) A phase II trial of gemcitabine and irinotecan in patients with refractory or relapsed non-small cell lung cancer. J Clin Oncol 22(Suppl. 14):697s (abstract 2710)","DOI":"10.1200\/jco.2004.22.14_suppl.7325"},{"key":"242_CR29","first-page":"4205","volume":"23","author":"D Pectasides","year":"2003","unstructured":"Pectasides D, Mylonakis N, Farmakis D, Nikolaou M, Koumpou M, Katselis I, Gaglia A, Kostopoulou V, Karabelis A, Kosmas C (2003) Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study. Anticancer Res 23:4205\u20134211","journal-title":"Anticancer Res"},{"key":"242_CR30","doi-asserted-by":"crossref","unstructured":"Castellano DE, Ciruelos E, Garcia-Giron C, Lopez-Martin A, Garrido P, Jimeno A, Duran I, Garcia-Velasco A, Cortes-Funes H, Paz-Ares L (2003) Phase II trial of biweekly irinotecan plus gemcitabine combination in refractory or relapsed small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 22:674 (abstract 2710)","DOI":"10.1016\/S0169-5002(03)92537-2"},{"key":"242_CR31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0959-8049(00)00419-6","volume":"37","author":"C Kosmas","year":"2001","unstructured":"Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, Malamos N, Antonopoulos M, Kalofonos HP (2001) Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane\u00a0+\u00a0platinum-based regimens. Eur J Cancer 37:972\u2013978","journal-title":"Eur J Cancer"},{"key":"242_CR32","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/1097-0142(20011201)92:11<2902::AID-CNCR10103>3.0.CO;2-O","volume":"92","author":"C Kosmas","year":"2001","unstructured":"Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP (2001) Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 92:2902\u20132910","journal-title":"Cancer"},{"key":"242_CR33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1040-8428(02)00081-1","volume":"45","author":"C Kosmas","year":"2003","unstructured":"Kosmas C, Tsavaris N, Mylonakis N, Kalofonos HP (2003) An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. Crit Rev Oncol Hematol 45:265\u2013275","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0242-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0242-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0242-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:21Z","timestamp":1559037981000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0242-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,11,2]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0242-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,19]]}}}